Additionally, tumor molecular markers, such as microsatellite status, CpG island methylator phenotype (CIMP) status, BRAF mutations, and KRAS mutations as well as tumor immune infiltration have been linked to different recurrence risks and survival outcomes in patients with stage III colon cancer [27, 28]. The gene discussed is KRAS; the disease is neoplasm.